Research ExplorerPublicationsUpdate on the diagnosis and treatment of neuromyelitis optic...

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management

Standard

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management. / Kümpfel, Tania; Giglhuber, Katrin; Aktas, Orhan; Ayzenberg, Ilya; Bellmann-Strobl, Judith; Häußler, Vivien; Havla, Joachim; Hellwig, Kerstin; Hümmert, Martin W; Jarius, Sven; Kleiter, Ingo; Klotz, Luisa; Krumbholz, Markus; Paul, Friedemann; Ringelstein, Marius; Ruprecht, Klemens; Senel, Makbule; Stellmann, Jan-Patrick; Bergh, Florian Then; Trebst, Corinna; Tumani, Hayrettin; Warnke, Clemens; Wildemann, Brigitte; Berthele, Achim; Neuromyelitis Optica Study Group (NEMOS).

In: J NEUROL, Vol. 271, No. 1, 01.2024, p. 141-176.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Kümpfel, T, Giglhuber, K, Aktas, O, Ayzenberg, I, Bellmann-Strobl, J, Häußler, V, Havla, J, Hellwig, K, Hümmert, MW, Jarius, S, Kleiter, I, Klotz, L, Krumbholz, M, Paul, F, Ringelstein, M, Ruprecht, K, Senel, M, Stellmann, J-P, Bergh, FT, Trebst, C, Tumani, H, Warnke, C, Wildemann, B, Berthele, A & Neuromyelitis Optica Study Group (NEMOS) 2024, 'Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management', J NEUROL, vol. 271, no. 1, pp. 141-176. https://doi.org/10.1007/s00415-023-11910-z

APA

Kümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Jarius, S., Kleiter, I., Klotz, L., Krumbholz, M., Paul, F., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J-P., Bergh, F. T., ... Neuromyelitis Optica Study Group (NEMOS) (2024). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management. J NEUROL, 271(1), 141-176. https://doi.org/10.1007/s00415-023-11910-z

Vancouver

Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management. J NEUROL. 2024 Jan;271(1):141-176. https://doi.org/10.1007/s00415-023-11910-z

Bibtex

@article{3a0f087f44784e55bea936efc0355305,
title = "Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management",
abstract = "This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.",
author = "Tania K{\"u}mpfel and Katrin Giglhuber and Orhan Aktas and Ilya Ayzenberg and Judith Bellmann-Strobl and Vivien H{\"a}u{\ss}ler and Joachim Havla and Kerstin Hellwig and H{\"u}mmert, {Martin W} and Sven Jarius and Ingo Kleiter and Luisa Klotz and Markus Krumbholz and Friedemann Paul and Marius Ringelstein and Klemens Ruprecht and Makbule Senel and Jan-Patrick Stellmann and Bergh, {Florian Then} and Corinna Trebst and Hayrettin Tumani and Clemens Warnke and Brigitte Wildemann and Achim Berthele and {Neuromyelitis Optica Study Group (NEMOS)}",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = jan,
doi = "10.1007/s00415-023-11910-z",
language = "English",
volume = "271",
pages = "141--176",
journal = "J NEUROL",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

RIS

TY - JOUR

T1 - Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II. Attack therapy and long-term management

AU - Kümpfel, Tania

AU - Giglhuber, Katrin

AU - Aktas, Orhan

AU - Ayzenberg, Ilya

AU - Bellmann-Strobl, Judith

AU - Häußler, Vivien

AU - Havla, Joachim

AU - Hellwig, Kerstin

AU - Hümmert, Martin W

AU - Jarius, Sven

AU - Kleiter, Ingo

AU - Klotz, Luisa

AU - Krumbholz, Markus

AU - Paul, Friedemann

AU - Ringelstein, Marius

AU - Ruprecht, Klemens

AU - Senel, Makbule

AU - Stellmann, Jan-Patrick

AU - Bergh, Florian Then

AU - Trebst, Corinna

AU - Tumani, Hayrettin

AU - Warnke, Clemens

AU - Wildemann, Brigitte

AU - Berthele, Achim

AU - Neuromyelitis Optica Study Group (NEMOS)

N1 - © 2023. The Author(s).

PY - 2024/1

Y1 - 2024/1

N2 - This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.

AB - This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.

U2 - 10.1007/s00415-023-11910-z

DO - 10.1007/s00415-023-11910-z

M3 - SCORING: Review article

C2 - 37676297

VL - 271

SP - 141

EP - 176

JO - J NEUROL

JF - J NEUROL

SN - 0340-5354

IS - 1

ER -